sodium fusidate

CLINICAL USE

Antibacterial agent

DOSE IN NORMAL RENAL FUNCTION

Oral: 0.5–1 g (as sodium fusidate) every 8 hoursSuspension: 750 mg every 8 hours (as fusidic acid)IV: 500 mg (as sodium fusidate) every 8 hours

PHARMACOKINETICS

Molecular weight :538.7

%Protein binding :95

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :0.2

half-life – normal/ESRD (hrs) :10–15/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antivirals: concentration of both drugs increased in combination with ritonavir – avoid concomitant useStatins: increased risk of myopathy with simvastatin and atorvastatin especially in diabetics

ADMINISTRATION

Reconstition

Use buffered solution provided, then dilute in 500 mL sodium chloride 0.9%

Route

IV (peripherally), oral

Rate of Administration

Over 6 hours

Comments

Unlicensed administration: 500 mg/10 mL buffered solution diluted to 100 mL and given via a central line over 2–6 hoursMinimum peripheral volume: 500 mg in 250 mL. (UK Critical Care Group Minimum Infusion Volumes for fluid restricted critically ill patients, 3rd Edition, 2006)

OTHER INFORMATION

500 mg reconstituted with buffer contains 3.1 mmol sodium and 1.1 mmol of phosphate
Can be administered neat via central line

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home